MISSISSAUGA, ON, April 19, 2012 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it is presenting its newest line of advanced wound care products from April 19th to 22nd at the Spring Symposium on Advanced Wound Care ("Spring SAWC") in Atlanta, GA. Covalon's new wound care products include:
- SurgiClearTM antimicrobial clear silicone adhesive film dressing,
- CovaStatTM fast-acting haemostatic wound dressing,
- CovaSorbTM bioactive foam replacement wound dressing, and
- CovaGenTM negative pressure friendly biologically active wound contact layer dressing.
These exciting new products will be available for license or distribution, following regulatory clearance. Covalon's ColActive® Plus Ag collagen wound dressing for treatment of chronic wounds and diabetic foot ulcers has been marketed and sold in the United States and elsewhere since 2005.
Now in its 25th year, Spring SAWC is the largest annual gathering of wound care clinicians in the United States. The symposium provides an opportunity for Covalon to showcase its new wound care products to more than 2,000 physicians, podiatrists, nurses, therapists, and researchers and over 200 leading wound care product manufacturers, wholesalers and distributors are expected to attend the 2012 Spring SAWC meeting.
"Our team is extremely excited to present our newest advanced wound care products at this year's Spring SAWC meeting," said Brian Pedlar, Covalon's Chief Executive Officer. "We are looking forward to introducing our new line-up of products to our growing domestic and international distribution channels and to medical product companies who are looking to license breakthrough new products."
To learn more about Covalon's products and services, please visit us at booth 134 in the Georgia World Congress Center from April 19th to 22nd or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at email@example.com.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
For further information: